Automate Your Wheel Strategy on RXST
With Tiblio's Option Bot, you can configure your own wheel strategy including RXST - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RXST
- Rev/Share 3.9103
- Book/Share 6.895
- PB 1.1283
- Debt/Equity 0.0431
- CurrentRatio 12.6826
- ROIC -0.1268
- MktCap 316155860.0
- FreeCF/Share -0.5084
- PFCF -15.3496
- PE -11.8729
- Debt/Assets 0.0385
- DivYield 0
- ROE -0.0954
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | RXST | Morgan Stanley | Overweight | Equal Weight | -- | $9 | July 15, 2025 |
| Downgrade | RXST | Jefferies | Buy | Hold | -- | $9 | July 10, 2025 |
| Downgrade | RXST | BTIG Research | Buy | Neutral | -- | -- | July 9, 2025 |
| Downgrade | RXST | Wells Fargo | Overweight | Equal Weight | -- | $9 | July 9, 2025 |
| Downgrade | RXST | Oppenheimer | Outperform | Perform | -- | -- | July 9, 2025 |
| Upgrade | RXST | Wells Fargo | Equal Weight | Overweight | -- | $25 | May 19, 2025 |
| Initiation | RXST | Piper Sandler | -- | Neutral | -- | $18 | April 15, 2025 |
| Downgrade | RXST | UBS | Buy | Neutral | -- | $16 | April 9, 2025 |
| Downgrade | RXST | JP Morgan | Overweight | Underweight | $40 | $17 | April 4, 2025 |
| Downgrade | RXST | BofA Securities | Buy | Underperform | $36 | $22 | April 3, 2025 |
News
Securities Fraud Investigation Into RxSight, Inc. (RXST) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Published: July 16, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON RXSIGHT, INC. (RXST), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On July 9, 2025, RxSight reported preliminary.
Read More
Securities Fraud Investigation Into RxSight, Inc. (RXST) Continues – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
Published: July 15, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON RXSIGHT, INC. (RXST), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is the Investigation About? On July 9, 2025, RxSight reported preliminary second quarter 2025 financial.
Read More
INVESTOR ALERT: Investigation of RxSight, Inc. (RXST) Announced by Holzer & Holzer, LLC
Published: July 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, July 11, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) complied with federal securities laws. On July 8, 2025, RxSight announced select preliminary financial results for the second quarter 2025 and revised full-year 2025 guidance, revealing declines in revenue, Light Delivery Devices sales, and usage of Light Adjustable Lenses. Following this news, the price of the Company's stock dropped.
Read More
Johnson Fistel Begins Investigation on Behalf of RxSight, Inc. (RXST) Shareholders
Published: July 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether RxSight, Inc. (NASDAQ: RXST), or any of its executive officers, violated federal securities laws by making false or misleading statements or failing to disclose material information to investors.
Read More
RxSight, Inc. (RXST) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Published: July 11, 2025 by: Business Wire
Sentiment: Neutral
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN RXSIGHT, INC. (RXST), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howa.
Read More
FMS vs. RXST: Which Stock Is the Better Value Option?
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical - Instruments sector might want to consider either Fresenius (FMS) or RxSight, Inc. (RXST). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
FMS or RXST: Which Is the Better Value Stock Right Now?
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical - Instruments sector might want to consider either Fresenius (FMS) or RxSight, Inc. (RXST). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
RxSight, Inc. (RXST) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
RxSight, Inc. (NASDAQ:RXST ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Oliver Moravcevic - Vice President, Investor Relations Ron Kurtz - President & Chief Executive Officer Shelley Thunen - Chief Financial Officer Conference Call Participants Xuyang Li - Jefferies Patrick Wood - Morgan Stanley Steve Lichtman - Oppenheimer David Saxon - Needham & Company Adam Maeder - Piper Sandler Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Craig Bijou - Bank of America Tom Stephan - Stifel Operator Thank you for standing by. At this time, I would like to welcome everyone to …
Read More
RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
RxSight, Inc. (RXST) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.12 per share a year ago.
Read More
RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance
Published: April 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary revenue results for the first quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Thursday, April 3, 2025, at 8:00 a.m. Eastern Time.
Read More
RxSight, Inc. (RXST) Misses Q4 Earnings Estimates
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Negative
RxSight, Inc. (RXST) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.26 per share a year ago.
Read More
About RxSight, Inc. (RXST)
- IPO Date 2021-07-30
- Website https://www.rxsight.com
- Industry Medical - Devices
- CEO Ronald M. Kurtz
- Employees 498